NCT03926026View on ClinicalTrials.gov

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

October 21, 2019

Study Completion Date

October 21, 2019

Conditions
Blepharitis
Interventions
DRUG

Fluticasone Propionate

NCX 4251 Ophthalmic Suspension, 0.1%

DRUG

Placebo

NCX 4251 Ophthalmic Suspension, 0%

Trial Locations (1)

78731

Texan Eye, Austin

All Listed Sponsors
lead

Nicox Ophthalmics, Inc.

INDUSTRY

NCT03926026 - Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis | Biotech Hunter | Biotech Hunter